Palmitoyl Tripeptide-1
Tier 2 · PreclinicalThe strongest evidence present is Tier 1: a clinical trial in 30 female participants over 8 weeks (src-17) and reference-cited human clinical/RCT studies of topical formulations (src-6, src-34, src-35). However, most of these positive human outcomes involve either the Matrixyl 3000 combination (Pal-Tripeptide-1 + Pal-Tetrapeptide-7) or timed regimens with baicalin, not the isolated peptide. Multiple sources (src-5, src-8, src-16) note that Pal-GHK alone has not been tested in humans, that no published study has measured its in vivo penetration, and that most efficacy data is supplier-associated (Sederma/Croda) with thin independent replication. Much mechanistic and pharmacokinetic detail is from vendor descriptions, in vitro fibroblast cultures, and Franz diffusion-cell models rather than human pharmacokinetic studies.
- Half-life
- ~7 h
- Routes
- Topical (cosmetic formulation)
- Goals
- Skin anti-aging / dermal remodeling · Wrinkle reduction · Skin firmness and elasticity · Wound healing / tissue repair (reported)
- Cost / mg
- Not recorded
How it works
According to peptide information sources, Palmitoyl Tripeptide-1 (Pal-GHK) is the small collagen-fragment peptide GHK (glycine-histidine-lysine) with a fatty (palmitic acid) tail attached to its N-terminus. Sources explain that GHK is naturally released when type I collagen breaks down and acts as a 'matrikine' — a signal that tells skin fibroblast cells to make new collagen and other matrix components. The fatty tail is described as a delivery vehicle that helps the otherwise water-loving peptide cross the oily outer skin barrier. Reference and reference-cited studies report that, in lab-grown skin cells, the peptide stimulates collagen and elastin production, appears to work through the TGF-β signaling pathway, and may reduce inflammation. Several sources stress that Pal-GHK is a copper-free analog and, unlike GHK-Cu, does not deliver copper ions.
Overview
Overview
Palmitoyl Tripeptide-1 (also called Pal-GHK or palmitoyl oligopeptide) is described across the source set as a synthetic lipopeptide: the tripeptide glycyl-L-histidyl-L-lysine (GHK) conjugated at its N-terminus to palmitic acid, a 16-carbon saturated fatty acid. The CIR Expert Panel describes it, alongside related peptides, as functioning primarily as a skin conditioning agent in cosmetics.
Origin and structure
A peptide information site states the GHK sequence was originally identified in 1973 by Loren Pickart and Marguerite Thaler as a factor in young human plasma capable of stimulating aged liver tissue to synthesize proteins in a pattern resembling younger tissue. The CIR review notes GHK is a liver growth factor peptide and a fragment of type I collagen; src-3 and src-19 (via src-8) describe GHK as present within the alpha-2(I) chain of type I collagen and liberated by proteases during collagen degradation, functioning as a matrikine that signals surrounding cells to synthesize new matrix. Several sources (src-6, src-7, src-8) emphasize that Pal-GHK is a copper-free structural analog of GHK-Cu and does not deliver copper ions — a distinction blurred by src-10 and src-18, which discuss it in the context of the copper-containing pal-GHK-Cu, a distinct compound.
Reported physicochemical data conflict: src-2 gives a base-peptide molecular weight of 342.5 Da, while src-3, src-8 and src-9 report ~578-578.79 g/mol with formula C30H54N6O5, and src-7 reports 578.8 g/mol with formula C26H48N4O5. CAS number 147732-56-7 is cited by src-3, src-7 and src-9; src-9 additionally gives PubChem ID 10231864 and uniquely attributes development to Lipotec S.A. in 2002 — an attribution that conflicts with src-3's attribution of the Matrixyl 3000 complex to Sederma.
Formulation context
A peptide information site states Palmitoyl Tripeptide-1 is one of two active components of Matrixyl 3000, Sederma's dual-peptide complex combining Pal-GHK with palmitoyl tetrapeptide-7 (Pal-GQPR), and is incorporated into commercial formulations including Haloxyl and Maxi-Lip (src-3). A peptide reference site notes that within Matrixyl 3000, Pal-Tripeptide-1 drives collagen neosynthesis while Palmitoyl Tetrapeptide-7 reduces inflammatory cytokine production, particularly IL-6 (src-4, src-5).
Reported activity and evidence
In vitro and reference-cited work reports collagen-stimulating activity. Lintner et al. (2009) reported that in human dermal fibroblast cultures the peptide stimulated collagen synthesis dose-dependently, with significant upregulation of procollagen I and III and increases in fibronectin and glycosaminoglycan synthesis — an effect described as comparable to or greater than retinol at equivalent concentrations under certain assay conditions (src-4). A vendor cites 2.3-fold increases in procollagen at 5-10 ppm and, in human dermal fibroblast cultures, a 2.3-fold rise in type I collagen mRNA and 1.8-fold rise in elastin after 72-hour exposure at 10 ppm (src-2, src-11 for methodology of related peptides). A tier-2 review states that, based on cellular studies, GHK can be considered an anti-wrinkle ingredient with tissue-regeneration, collagen/glycosaminoglycan-enhancing, nerve-outgrowth, angiogenic and wound-healing properties (src-16).
Human data largely involve combinations rather than the isolated peptide. A reference site reports clinical evaluation of Matrixyl 3000 at 3% twice daily for 56 days showed measurable improvements in wrinkle depth, firmness and texture (src-4); Robinson et al. (2005) documented wrinkle-volume reduction and improved skin roughness by profilometry (src-4); a peptide list site reports wrinkle-depth reductions of about 20-30% versus placebo at 8-16 weeks of twice-daily Matrixyl 3000 use (src-5). A peptide reference site reports clinical studies with twice-daily creams containing ~3 ppm Pal-GHK improving periorbital wrinkle depth and length, and cites a 4-week eye-zone study finding a 39% reduction in wrinkle length, 23% reduction in wrinkle depth, and 17% reduction in overall roughness versus vehicle (src-6, src-34, src-35). A clinical trial in 30 female participants over 8 weeks reported that nighttime PT-1 as part of a timed regimen (with daytime baicalin) improved skin luminance (+16.29%), reduced nasolabial fold depth (-36.35%) and improved firmness (R2: +24.35%), with an animal component reporting increased collagen fiber density (src-17). A single tier-4 site makes the largest claims — up to 55% collagen density increase and 19% elasticity improvement over 12 weeks (src-9) — which are not corroborated elsewhere.
Important evidence caveats
Multiple sources caution that Pal-GHK alone has not been tested in humans and that no published study has measured its in vivo penetration (src-8, src-16). A peptide list site notes most published efficacy data is supplier-associated (Sederma/Croda), that independent replication at clinically relevant concentrations is thin, and assigns a 58% overall confidence rating (src-5); a tier-2 review notes a 'surprising absence' of clinical studies on GHK-Cu and Pal-GHK despite their wide cosmetic use (src-16). Src-8 characterizes the evidence base as 1 human study, 2 animal studies and 3 in vitro studies.
What the research shows
156 findings extracted from the 19 sources cited below, strongest evidence first within each group. Every one links to the source it came from.
What human studies found
Based on 5 human trial findings, 8 human study findings, 1 animal finding, 8 in vitro findings, 4 expert opinion findings and 1 anecdotal finding.
human trialClinical studies demonstrate measurable improvements in periorbital wrinkle depth and length with twice-daily application of creams containing Palmitoyl Tripeptide-1 at concentrations of approximately 3 ppm2
human trialA 4-week eye zone study found 39% reduction in wrinkle length, 23% reduction in wrinkle depth, and 17% reduction in overall skin roughness versus vehicle2
human trialTopical PT-1 applied at nighttime as part of a timed regimen improved skin luminance (+16.29%)3
human trialTopical PT-1 applied at nighttime as part of a timed regimen reduced nasolabial fold depth (-36.35%)3
human trialTopical PT-1 applied at nighttime as part of a timed regimen improved skin firmness (R2: +24.35%)3
human studyMatrixyl 3000 clinical studies show measurable wrinkle-depth reductions around 20–30% versus placebo at 8–16 weeks of twice-daily use11
human studyClinical evaluation of Matrixyl 3000 (Pal-Tripeptide-1 + Pal-Tetrapeptide-7) applied at 3% concentration twice daily for 56 days demonstrated measurable improvements in wrinkle depth, skin firmness, and overall skin texture12
human studyRobinson et al. (2005) documented wrinkle volume reduction and improvements in skin roughness parameters using profilometric analysis12
Show the remaining 19
human studyIn clinical studies combined with another peptide (as Matrixyl 3000), it shows real but modest wrinkle reduction14
human studySmall clinical panels show wrinkle reduction with Matrixyl 3000 (combination of Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7)14
human studyTopical clinical studies using palmitoyl tripeptide-1 show measurable improvements in skin firmness, wrinkle depth, and dermal density over 8–12 week periods15
human studyPalmitoyl tripeptide-1 applied at nighttime synergistically boosted collagen synthesis when combined with daytime baicalin application15
human studyClinical studies demonstrate up to 55% collagen density increase and 19% elasticity improvement over 12 weeks of consistent application18
animalTime-coordinated nighttime application of PT-1 in combination with daytime baicalin increases collagen fiber density3
in vitroBased on cellular studies, GHK can be considered as an anti-wrinkle ingredient7
in vitroIn vitro studies using human dermal fibroblast cultures demonstrate that Palmitoyl Tripeptide-1 stimulates collagen synthesis in a dose-dependent manner12
in vitroLintner et al. (2009) reported significant upregulation of procollagen I and III production, with concomitant increases in fibronectin and glycosaminoglycan synthesis12
in vitroThe effect was comparable to or greater than that of retinol at equivalent concentrations in certain assay conditions12
in vitroIn lab dishes, it does what GHK does — stimulates collagen production, reduces inflammation, remodels tissue14
in vitroFibroblast culture studies show PAL-GHK upregulates collagen types I and III production15
in vitroIn vitro studies demonstrate 2.3-fold increases in procollagen production at concentrations of 5-10 ppm17
in vitroType I collagen mRNA expression increased 2.3-fold and elastin production rose 1.8-fold after 72-hour exposure at 10 ppm concentrations in human dermal fibroblast cultures17
expert opinionThere is a surprising absence of clinical studies using GHK-Cu and Pal-GHK7
expert opinionTrials of the isolated peptide at matched concentrations are more limited compared to Matrixyl 300011
expert opinionMost published efficacy data is supplier-associated (Sederma/Croda) and independent replication at clinically relevant concentrations is thin11
expert opinionNobody has tested Pal-GHK alone in humans14
anecdotalUsers report noticeable improvements in skin firmness, wrinkle reduction, enhanced healing from procedures or trauma, and improved overall skin quality within weeks10
How it works
Based on 2 human trial findings, 1 human study finding, 14 in vitro findings, 38 expert opinion findings and 14 theoretical findings.
human trialPalmitoyl tripeptide-1 (PT-1) at nighttime boosts nighttime collagen synthesis3
human trialPT-1 works synergistically with daytime baicalin to optimize collagen metabolism through circadian-coordinated application3
human studyThe GHK sequence was originally identified in 1973 by Loren Pickart and Marguerite Thaler as a factor in young human plasma capable of stimulating aged liver tissue to synthesize proteins in a pattern resembling that of younger tissue16
in vitroIt stimulates fibroblast synthesis of collagen I and III, glycosaminoglycans, and elastin2
in vitroThe GHK sequence binds fibroblast surface receptors and activates intracellular TGF-β pathway components and downstream collagen gene transcription (COL1A1, COL3A1)2
in vitroIn vitro studies confirm stimulation of collagen I, III, and glycosaminoglycan synthesis at sub-micromolar concentrations2
in vitroIt has also been shown to modulate MMP expression, reducing collagen degradation in UV-aged skin models2
in vitroPalmitoyl-containing peptides (palmitoyl hexapeptide-12, caffeoyl hexapeptide-9, palmitoyl pentapeptide-4) demonstrate sequence homology with extracellular matrix proteins in the skin (collagen, elastin, fibronectin) without safety concerns4
Show the remaining 61
in vitroCosmetic peptides including Palmitoyl Tripeptide-1 have claimed biological activities including signaling to increase collagen and hyaluronic acid production5
in vitroPalmitoyl copper peptide (pal-GHK-Cu) is composed of glycyl-L-histidyl-L-lysine-copper6
in vitroCP-AcT effectively promotes melanin production in both human A375 and mouse B16 melanoma cell lines6
in vitroCP-AcT affects tyrosinase activity both extracellularly and intracellularly6
in vitroCP-AcT affects expression of melanin-related genes in A375 cells6
in vitroCP-AcT affects expression of tyrosinase (TYR), dopachrome tautomerase (DCT), and endothelin 3 (EDN3) proteins6
in vitroGHK has capability of tissue regeneration and enhancement of collagen and glycosaminoglycans synthesis7
in vitroGHK is able to increase nerve outgrowth and angiogenesis7
in vitroPAL-GHK may downregulate pro-inflammatory cytokines in skin cell models15
expert opinionPalmitoyl tripeptide-1 has the peptide sequence Gly-His-Lys (GHK)1
expert opinionThe GHK sequence is a liver growth factor peptide and a fragment of type I collagen1
expert opinionPalmitoyl tripeptide-1 is a fatty acyl derivative with a palmitic acid group attached to the N-terminus of the tripeptide1
expert opinionA safety evaluation framework for peptides in cosmetics incorporates bioinformatic tools including BLASTp, ToxinPred3.0, Peptipedia, BIOPEP-UWM, AllerCatPro 2.0, and IEDB4
expert opinionTripeptides regulate key processes such as cell migration, proliferation, and differentiation9
expert opinionTripeptides modulate inflammation, promote angiogenesis, and facilitate extracellular matrix (ECM) remodeling9
expert opinionTripeptides can stimulate fibroblast migration and enhance collagen deposition9
expert opinionPal-GHK is the lipid-conjugated version of the copper peptide GHK, engineered with a palmitoyl fatty acid chain for superior skin penetration and cellular absorption compared to non-lipidated GHK10
expert opinionIt activates fibroblasts to boost collagen and elastin synthesis10
expert opinionReduces inflammation through antioxidant mechanisms10
expert opinionA powerful anti-aging peptide that stimulates the production of collagen and glycosaminoglycans in the skin10
expert opinionResearch Goal: Analyzing the synthesis of Type I Collagen and Fibronectin in the extracellular matrix to improve skin firmness and elasticity10
expert opinionPalmitoyl Tripeptide-1 is a lipopeptide consisting of palmitic acid linked to the tripeptide GHK11
expert opinionFunctions as a matrikine — a messenger that signals fibroblasts to produce new collagen, elastin, and glycosaminoglycans11
expert opinionThe GHK sequence is a matrikine derived from type I collagen, fibronectin, and SPARC11
expert opinionWhen detected by dermal fibroblasts via TGF-beta receptor signaling, it activates the wound-healing cascade: upregulation of collagen types I, III, and IV synthesis, increased elastin production, and enhanced glycosaminoglycan deposition11
expert opinionIn Matrixyl 3000, it is paired with Palmitoyl Tetrapeptide-7, which suppresses IL-6 and other pro-inflammatory cytokines11
expert opinionPalmitoyl oligopeptide ingredients are structurally related by an identical fatty, hydrophobic tail connected to a variable sequence of peptides13
expert opinionFatty acid peptide ingredients are created using solid-phase peptide synthesis13
expert opinionSome small peptides are potent stimulators of angiogenesis13
expert opinionGHK is a natural collagen fragment released when collagen breaks down14
expert opinionGHK's job is to tell nearby skin cells that repairs are needed: make more collagen, reorganize the scaffold, clean up the damage14
expert opinionPalmitoyl Tripeptide-1 is GHK with a fatty tail bolted on so it can slip through the oily barrier of your skin14
expert opinionGHK is one of the best-studied matrikines in the literature: a natural collagen fragment that stimulates fibroblast proliferation, drives collagen synthesis, suppresses inflammatory cytokines, and modulates matrix metalloproteinase activity14
expert opinionGHK stimulates fibroblast collagen synthesis via integrin α2β1; suppresses MMP-1 (collagenase); anti-inflammatory via IL-6 and TNF-α suppression14
expert opinionPAL-GHK (palmitoyl tripeptide-1) is a lipid-modified derivative of the GHK tripeptide with a palmitic acid chain replacing the copper(II) ion15
expert opinionPAL-GHK acts as a matrikine — a peptide fragment that signals fibroblasts to produce new collagen15
expert opinionCollagen synthesis stimulation appears mediated through TGF-β signalling15
expert opinionPAL-GHK does not deliver copper(II) ions15
expert opinionGHK is present as a sequence within the alpha-2(I) chain of type I collagen and is liberated by proteases during collagen degradation, functioning as a matrikine16
expert opinionThe matrikine concept describes how peptide fragments generated during ECM breakdown serve as feedback signals to surrounding cells, stimulating compensatory synthesis of new matrix components16
expert opinionPalmitoylation increases the peptide's lipophilicity by 100- to 1000-fold, enabling efficient partitioning into the intercellular lipid matrix of the stratum corneum and delivery to the dermis where fibroblasts reside16
expert opinionThe GHK tripeptide sequence carries the biological activity while the palmitoyl chain serves exclusively as a delivery vehicle16
expert opinionWhen fibroblasts detect elevated levels of propeptide fragments, they respond by upregulating synthesis of new extracellular matrix components16
expert opinionMolecular weight is 342.5 Da for the base peptide17
expert opinionPalmitic acid conjugation increases lipophilicity by 16-fold compared to unconjugated GHK17
expert opinionPalmitic acid conjugation enhances dermal penetration by 300-400% compared to the parent compound17
expert opinionLog P = 3.2 provides necessary lipophilicity for membrane permeation17
theoreticalPalmitoyl Tripeptide-1 is a lipopeptide consisting of the tripeptide sequence Gly-His-Lys conjugated to a palmitic acid chain2
theoreticalIt is a structural analog of GHK (the copper-binding tripeptide) but without copper coordination, functioning instead as a matrikine signal peptide2
theoreticalPalmitoylated GHK (Pal-GHK) is a palmitoylated derivative of GHK peptide7
theoreticalPalmitoyl Tripeptide-1 stimulates collagen I, III, and fibronectin synthesis through TGF-β pathway activation12
theoreticalPalmitoyl Tripeptide-1 belongs to the class of matrikine peptides -- small peptide fragments released during extracellular matrix turnover that regulate cell activities including proliferation, migration, and matrix synthesis12
theoreticalThe palmitoyl (C16 fatty acid) moiety is attached to enhance lipophilicity and improve penetration through the stratum corneum12
theoreticalPal-Tripeptide-1 drives collagen neosynthesis, while Palmitoyl Tetrapeptide-7 reduces inflammatory cytokine production (particularly IL-6)12
theoreticalPal-Tripeptide-1 functions as a signal peptide that mimics the small peptide fragments generated during collagen degradation12
theoreticalThe peptide upregulates TGF-β production, which in turn activates Smad-dependent transcription of procollagen genes12
theoreticalPal-Tripeptide-1 upregulates hyaluronic acid synthase expression, contributing to improved dermal hydration12
theoreticalThe peptide modulates MMP expression, reducing enzymatic degradation of existing collagen while simultaneously promoting new synthesis12
theoreticalPalmitoyl tripeptide-1 (Pal-GHK) is a synthetic lipopeptide consisting of the tripeptide glycyl-L-histidyl-L-lysine (GHK) conjugated at its N-terminus to palmitic acid, a 16-carbon saturated fatty acid16
theoreticalDirectly activates TGF-β pathway in dermal fibroblasts to stimulate synthesis of collagen types I, III, IV, and VII along with other ECM proteins18
theoreticalComprehensive ECM remodeling including elastin, glycosaminoglycans, and decorin production restores structural integrity to aging skin18
Dosing
Based on 2 human trial findings and 9 expert opinion findings.
human trialEffective at 0.5–3 ppm pure peptide in finished formulation2
human trialTypical topical range is 2–5% applied twice daily2
expert opinionTypical use concentrations of these ingredients are < 10 ppm1
expert opinionFormulated as a topical cream or serum, often used at 100ppm to 500ppm (parts per million)10
expert opinionWrinkle Reduction protocol: 3%–5% Complex applied twice daily10
expert opinionSkin Barrier Support protocol: 1%–2% Complex applied once daily10
expert opinionStandard topical dosage range is 2-10 ppm in cosmetic formulations, with most commercial products containing 3-5 ppm concentrations17
expert opinionTwice-daily application protocols show superior efficacy compared to single daily dosing in 12-week comparative studies measuring dermal thickness via ultrasound imaging17
How the body handles it
Based on 4 in vitro findings, 10 expert opinion findings and 6 theoretical findings.
in vitroMetal complexation and chemical modification with a hydrophobic moiety increase permeability of GHK peptide7
in vitroCell penetrating peptides seem promising to increase skin permeation of GHK and its derivatives7
in vitroFormulation influences pal-KTTKS availability8
in vitroBioavailability studies using Franz diffusion cells show that Pal-GHK achieves 12-15% transdermal penetration within 24 hours, compared to 2-3% for unconjugated GHK at equivalent concentrations17
expert opinionApplied topically, Pal-GHK penetrates to the dermal layer where it exerts maximum effect10
expert opinionThe addition of palmitoyl dramatically enhances bioavailability compared to GHK-Cu alone10
expert opinionThe palmitoyl modification (C16 fatty acid) dramatically improves penetration through the lipid-rich stratum corneum compared to the unmodified GHK tripeptide11
expert opinionGHK is a hydrophilic tripeptide that cannot easily cross the lipophilic stratum corneum14
Show the remaining 12
expert opinionNo published study has measured Pal-GHK penetration in vivo14
expert opinionUnmodified GHK tripeptide has poor topical bioavailability due to its hydrophilic nature and low partition coefficient15
expert opinionHalf-life in aqueous solutions is 6-8 hours, extended to 24-48 hours in lipid-based carriers due to palmitoyl conjugation17
expert opinionMolecular weight of 342.5 Da falls within the optimal range for topical delivery (under 500 Da)17
expert opinionRapid initial clearance from application site with t½ = 6-8 hours followed by sustained dermal depot release over 24-48 hours due to lipid sequestration17
expert opinionLiposomal suspension formulation achieves 18-22% transdermal bioavailability17
theoreticalThe palmitoyl fatty acid chain increases the molecule's lipophilicity, enabling penetration through the stratum corneum into the viable epidermis and dermis2
theoreticalSkin pretreatment with microneedles has the potential to enhance permeation of such peptides7
theoreticalThe C16 palmitic acid chain increases lipophilicity sufficiently to cross the skin barrier15
theoreticalEnhanced topical penetration via palmitoyl lipid modification; reaches dermis where fibroblasts reside18
theoreticalPeptide is susceptible to enzymatic degradation in skin but palmitoylation improves stability compared to unmodified GHK18
theoreticalActs mainly at the skin; little reaches the bloodstream18
Safety and side effects
Based on 1 in vitro finding, 6 expert opinion findings and 2 theoretical findings.
in vitroCP-AcT (palmitoyl copper peptide and acetyl tyrosine combination) showed no cytotoxicity at tested concentrations in HaCat, HFF, A375, and B16 cells6
expert opinionThe Panel concluded that these ingredients are safe in the present practices of use and concentration in cosmetics based on low use concentrations and negative safety test data1
expert opinionThe CIR Expert Panel has assessed Palmitoyl Tripeptide-1 as safe for cosmetic use2
expert opinionExceptionally high safety profile when used topically; it is non-irritating and very well-tolerated by most skin types10
expert opinionPalmitoyl tripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 are safe in the present practices of use and concentration13
expert opinionPal-GHK is not approved for injection and is available for research purposes only17
expert opinionPal-GHK is a research-only compound not FDA-approved for therapeutic use and prohibited for human consumption outside clinical trials17
theoreticalPeptide ingredients encounter challenges mainly due to their hydrophilic nature (high aqueous solubility and low partition coefficient) and instability7
Show the remaining 1
theoreticalAngiogenic activity in small peptides might promote tumor growth and metastasis in people with undiagnosed skin cancer13
What people use it for
Based on 1 human trial finding, 2 in vitro findings, 11 expert opinion findings and 3 theoretical findings.
human trialResults typically visible after 4–8 weeks of consistent use2
in vitroPalmitoyl Tripeptide-1 is a commercially available cosmetic peptide5
in vitroGHK has properties for wound healing and prevention/reduction of wrinkles7
expert opinionPalmitoyl tripeptide-1, palmitoyl hexapeptide-12, tripeptide-1, and copper tripeptide-1, and palmitoyl tetrapeptide-7 function primarily as skin conditioning agents1
expert opinionPalmitoyl tripeptide-1 is used in cosmetic products and requires safety evaluation4
expert opinionCopper peptide possesses anti-aging, anti-inflammatory, and wound healing properties6
expert opinionGHK-Cu and Pal-GHK are widely used in anti-wrinkle products available on the cosmetic market7
expert opinionEnhances wound healing, tissue repair, and anti-inflammatory effects10
Show the remaining 9
expert opinion4–8 weeks for visual results10
expert opinionPAL-GHK is engineered specifically for enhanced skin penetration in topical cosmetic formulations15
expert opinionGHK-Cu is studied across tissue repair, gene expression, and injectable research contexts while PAL-GHK is not15
expert opinionPalmitoyl tripeptide-1 is one of the two active components of Matrixyl 3000, Sederma's dual-peptide complex that combines Pal-GHK with palmitoyl tetrapeptide-7 (Pal-GQPR)16
expert opinionPalmitoyl tripeptide-1 is incorporated into commercial formulations including Haloxyl and Maxi-Lip16
expert opinionTypical application cycle is 12-24 weeks of continuous use to assess dermal remodeling effects based on collagen synthesis timelines17
theoreticalIt is a primary component of the Matrixyl 3000 system alongside Palmitoyl Tetrapeptide-72
theoreticalPalmitoyl peptides are anti-aging agents widely used in cosmetics8
theoreticalCollagen-stimulating matrikine peptide and key component of Matrixyl 3000 for comprehensive anti-aging skin renewal18
Other findings
Based on 3 in vitro findings.
in vitroCosmetic peptides are produced either through chemical synthesis or via biotechnological processes5
in vitroMS/MS detection is specific regarding placebo formulations for palmitoyl peptides8
in vitroPalmitoylated pentapeptide palmitoyl-lysyl-threonyl-threonyl-lysyl-serine (pal-KTTKS) can be reliably assayed in anti-wrinkle creams8
Points of contention
Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.
Contested
Molecular weight and formula reported inconsistently
Pal-GHK (Palmitoyl Tripeptide-1) Dosage Guide: How Much gives 342.5 Da for the base peptide; Palmitoyl Tripeptide-1 (Pal-GHK): Research Evidence & Safety Profile | PeptideInsight and Palmitoyl Tripeptide-1 Dosing, Need to Know… | Peptide Initiative give 578.79 g/mol with formula C30H54N6O5; PAL-GHK (Palmitoyl Tripeptide-1): Collagen-Boosting Peptide Research | PeptideGuide gives 578.8 g/mol with formula C26H48N4O5; Palmitoyl Tripeptide-1: Evidence & Research | Peptidings gives ~578 Da. The formulas and weights do not all agree.
- Tier 3Pal-GHK (Palmitoyl Tripeptide-1) Dosage Guide: How Much
- Tier 3Palmitoyl Tripeptide-1 (Pal-GHK): Research Evidence & Safety Profile | PeptideInsight
- Tier 3PAL-GHK (Palmitoyl Tripeptide-1): Collagen-Boosting Peptide Research | PeptideGuide
- Tier 3Palmitoyl Tripeptide-1: Evidence & Research | Peptidings
- Tier 4Palmitoyl Tripeptide-1 Dosing, Need to Know… | Peptide Initiative
Limited evidence
No human trials of Pal-GHK alone; efficacy data is largely supplier-associated
Palmitoyl Tripeptide-1: Evidence & Research | Peptidings and Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. state that Pal-GHK alone has not been tested in humans and that no published study has measured its in vivo penetration; Palmitoyl Tripeptide-1 (Pal-GHK, Biopeptide CL, Palmitoyl Oligopeptide) | Peptide List notes most efficacy data comes from the supplier (Sederma/Croda) with thin independent replication; Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. notes a surprising absence of clinical studies. Most positive clinical outcomes come from the Matrixyl 3000 combination (Pal-Tripeptide-1 + Pal-Tetrapeptide-7), not the isolated peptide.
Single source
Largest efficacy claims (55% collagen density, 19% elasticity) come from a single low-tier source
The 55% collagen density increase and 19% elasticity improvement over 12 weeks are reported only by a tier-4 site (Palmitoyl Tripeptide-1 Dosing, Need to Know… | Peptide Initiative); the developer date (2002, Lipotec) is also unique to this source and conflicts with attribution of Matrixyl 3000 to Sederma (Palmitoyl Tripeptide-1 (Pal-GHK): Research Evidence & Safety Profile | PeptideInsight).
Limited evidence
Many mechanism and pharmacokinetic figures are vendor/theoretical, not from human data
Half-lives (6-8 h aqueous, 24-48 h lipid), transdermal penetration percentages (12-15%, 18-22%, 8-12%), and fold-increases in collagen/elastin are drawn from vendor descriptions and in vitro/Franz-cell models (Pal-GHK (Palmitoyl Tripeptide-1) Dosage Guide: How Much), not human pharmacokinetic studies.
Other
Theoretical safety concern about angiogenesis raised by regulator
The CIR peptides review (Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts ...) notes that some small peptides stimulate angiogenesis, which might theoretically promote tumor growth in people with undiagnosed skin cancer, though the same panel concluded the ingredients are safe at present use concentrations.
Using it with other compounds
- TB-500Complementary
No documented conflict
TB-500 (thymosin β4 fragment) promotes cell migration, angiogenesis and anti-inflammatory tissue repair, while Pal-GHK drives collagen and matrix deposition. They converge on the same goal of tissue healing through distinct pathways (actin/cytoskeletal remodeling vs TGF-β collagen synthesis), so they can be viewed as complementary for repair contexts.
Tier 4Theoretical — not establishedWhat the research doesn't fully establish
Both peptides' mechanisms clearly establish the two claimed shared dimensions. (1) Anti-inflammatory: Palmitoyl Tripeptide-1 shows anti-inflammatory effects via IL-6 and TNF-α suppression (src-8, src-25); TB-500 shows anti-inflammatory effects via TNF-α, IL-1β, IL-6 reduction and NF-κB suppression. (2) Tissue_repair: Both are explicitly tagged and mechanistically described as promoting tissue repair—Pal-GHK through collagen/matrix synthesis and MMP modulation; TB-500 through cell migration, angiogenesis, and ECM remodeling. The explanation correctly identifies that they operate via distinct pathways (actin/cytoskeletal dynamics vs. TGF-β-driven collagen synthesis) while converging on tissue healing outcomes. This is a classic complementary relationship: non-overlapping mechanisms addressing the same functional goal. The proposed relationship type and shared dimensions are well-justified by the provided mechanism material.Shares anti inflammatory · tissue repair
- ElafinComplementary
May be complementary
In a skin-matrix context these are complementary: palmitoyl tripeptide-1 (Pal-GHK) stimulates collagen/elastin synthesis and suppresses MMPs, while elafin protects the dermal matrix by inhibiting elastase and other proteases that degrade elastin. One builds the matrix, the other guards it from enzymatic breakdown.
Tier 4Theoretical — not establishedWhat the research doesn't fully establish
The mechanisms clearly establish complementary roles in dermal matrix maintenance. Elafin inhibits neutrophil elastase, proteinase 3, cathepsin G, and endogenous vascular elastase—all proteases that degrade extracellular matrix components. Palmitoyl Tripeptide-1 stimulates collagen and elastin synthesis while suppressing MMP-1 and other matrix-degrading enzymes. Both peptides are tagged with anti_inflammatory, dermal_matrix, and tissue_repair. The proposed relationship accurately reflects their mechanistic complementarity: one actively synthesizes and protects matrix components (Pal-GHK via TGF-β pathway activation and MMP suppression), while the other protects existing matrix from protease degradation (Elafin via serine protease inhibition). This is a genuine functional complementarity supported by their distinct but synergistic mechanisms.Shares anti inflammatory · dermal matrix · tissue repair
- MatrixylComplementary
May be complementary
Both are palmitoylated matrikine peptides that drive fibroblasts to make more collagen and rebuild the dermal matrix, but they come from different collagen fragments and hit the pathway somewhat differently (Matrixyl/Pal-KTTKS via a fibroblast matrikine/TGF-beta route; Pal-GHK via broad gene modulation and MMP suppression). Because they converge on the same skin-firming, wrinkle-reducing outcome through non-identical routes, they are frequently layered together in topical formulas and are considered additive rather than redundant.
Tier 3Largely anecdotal — commonly discussedWhat the research doesn't fully establish
The mechanisms clearly justify this complementary relationship. Both peptides are palmitoylated matrikine fragments (Pal-KTTKS and Pal-GHK) that target fibroblast surface receptors and TGF-beta signaling to stimulate collagen synthesis and dermal matrix production. The shared dimensions (collagen_synthesis, dermal_matrix, tissue_repair) are explicitly documented in both mechanisms. The explanation accurately reflects mechanistic differences: Matrixyl operates primarily through matrikine and TGF-beta signaling with MMP/plasmin inhibition, while Pal-GHK additionally engages integrin α2β1, Smad-dependent transcription, and broader anti-inflammatory effects (IL-6, TNF-α suppression). Both converge on collagen I/III synthesis and wrinkle reduction but through partially distinct pathways, supporting the 'complementary' classification rather than redundancy. The claim that they are 'additive rather than redundant' is consistent with their overlapping but non-identical mechanism profiles as documented.Timing Topical use — can be applied together in the same routine.
Shares collagen synthesis · dermal matrix · tissue repair
- ArgirelineComplementary
May be complementary
Palmitoyl Tripeptide-1 (Pal-GHK) drives collagen, elastin and matrix synthesis in the dermis, complementing Argireline's relaxation of the facial muscles that fold the skin. One works on the underlying structural scaffold while the other reduces the repetitive creasing, so together they can address both static and dynamic contributors to lines.
Tier 4Theoretical — not establishedWhat the research doesn't fully establish
Both peptides' mechanisms support collagen_synthesis as a shared dimension. Argireline's mechanism explicitly includes 'Type I / type III collagen synthesis (animal data)' in its pathways and carries the 'collagen_synthesis' approved tag. Palmitoyl Tripeptide-1's mechanism prominently features 'Stimulation of collagen types I and III synthesis' and multiple pathway activations (TGF-β, Smad-dependent transcription of COL1A1/COL3A1) with the 'collagen_synthesis' approved tag. The proposed complementary relationship is justified: Argireline targets neuromuscular acetylcholine release to reduce dynamic wrinkles, while Palmitoyl Tripeptide-1 stimulates dermal matrix synthesis including collagen. Both contribute to collagen synthesis through different mechanisms (neurological vs. fibroblast signaling), making them mechanistically complementary for addressing both dynamic and static skin aging features as claimed.Shares collagen synthesis
- Palmitoyl Tetrapeptide-7Complementary
May be complementary
These two are the classic 'Matrixyl 3000' pairing in cosmetic formulations. Palmitoyl Tripeptide-1 (Pal-GHK) is a matrikine that actively drives fibroblasts to build new collagen, elastin and glycosaminoglycans, while Palmitoyl Tetrapeptide-7 works from the other direction — calming inflammatory cytokines (IL-6, IL-1β) and protecting the existing matrix from MMP-driven breakdown. Building plus protecting is exactly the kind of different-mechanism convergence that makes them a well-established, synergistic skin-firmness combination.
Tier 3Largely anecdotal — commonly discussedWhat the research doesn't fully establish
The mechanisms clearly justify this complementary relationship. Peptide B (Pal-GHK) actively stimulates collagen, elastin, and GAG synthesis via TGF-β and matrikine signaling pathways, while Peptide A (Pal-Tetrapeptide-7) suppresses IL-6 and IL-1β cytokine signaling and inhibits MMP-1-mediated matrix degradation. Both peptides share documented anti-inflammatory and dermal_matrix tags, and their mechanisms operate through distinct pathways that converge on matrix preservation and improvement: one through anabolic synthesis, the other through catabolic suppression and inflammation reduction. This represents genuine mechanistic complementarity rather than redundancy, supporting the proposed relationship and explanation.Timing Topical; apply together in the same routine.
Shares dermal matrix · anti inflammatory
- LeuphasylComplementary
May be complementary
Palmitoyl Tripeptide-1 (Pal-GHK) stimulates collagen, elastin and matrix synthesis through matrikine/TGF-β signaling, a structural route that is different from Leuphasyl's muscle-relaxing action. Pairing dermal-matrix building with dynamic-line relaxation targets wrinkles from two independent angles.
Tier 3Largely anecdotal — commonly discussedWhat the research doesn't fully establish
Both peptides' mechanisms justify the complementary relationship on the shared dimensions of dermal_matrix and collagen_synthesis. Leuphasyl targets dermal_matrix through acetylcholine pathway inhibition (reducing dynamic wrinkles via neuromuscular relaxation) and has approved tag 'dermal_matrix'. Palmitoyl Tripeptide-1 directly stimulates collagen types I, III, IV, VII synthesis and matrix components (elastin, fibronectin, GAGs, hyaluronic acid) via TGF-β/matrikine signaling with approved tags 'collagen_synthesis' and 'dermal_matrix'. The mechanisms describe mechanistically distinct pathways: Leuphasyl works through Gi/Go signaling and calcium channel inhibition affecting acetylcholine release, while Palmitoyl Tripeptide-1 works through integrin and TGF-β receptor activation of Smad-dependent collagen transcription. Both target wrinkle reduction but through independent mechanisms (dynamic relaxation vs. structural matrix building), supporting the complementary characterization.Timing Topical; apply together.
Shares dermal matrix · collagen synthesis
Safety and side effects
Safety
Regulatory / expert-panel assessment
The CIR Expert Panel concluded that palmitoyl tripeptide-1 and related ingredients are safe in the present practices of use and concentration in cosmetics, based on low use concentrations and negative safety test data (src-1, src-11). A bioinformatic safety evaluation using tools including BLASTp, ToxinPred3.0, Peptipedia, BIOPEP-UWM, AllerCatPro 2.0 and IEDB reports that palmitoyl-containing peptides demonstrate sequence homology with skin ECM proteins (collagen, elastin, fibronectin) without safety concerns (src-14). A peptide vendor states Pal-GHK has an exceptionally high safety profile when used topically, being non-irritating and well-tolerated by most skin types (src-10).
Theoretical concern raised by regulator
The CIR peptides review notes that some small peptides are potent stimulators of angiogenesis, and that this angiogenic activity might theoretically promote tumor growth and metastasis in people with undiagnosed skin cancer (src-11) — though the same panel concluded the ingredients are safe at present use concentrations. A separate review similarly notes tripeptides can promote angiogenesis and ECM remodeling (src-13). An in vitro study of a related palmitoyl copper peptide + acetyl tyrosine combination reported no cytotoxicity at tested concentrations (0-8 μg/mL) across HaCat, HFF, A375 and B16 cells, but also that it promoted melanin production in melanoma cell lines by affecting tyrosinase activity (src-18); note this concerns the copper-containing compound, which sources distinguish from copper-free Pal-GHK.
Not approved for injection or human consumption
A vendor dosing guide states Pal-GHK is not approved for injection, is available for research purposes only, is not FDA-approved for therapeutic use, and is prohibited for human consumption outside clinical trials (src-2). A peptide guide notes that while GHK-Cu is studied in tissue-repair, gene-expression and injectable research contexts, Pal-GHK is not (src-7).
Anecdotal reports
A peptide vendor reports that users describe noticeable improvements in skin firmness, wrinkle reduction, enhanced healing from procedures or trauma, and improved overall skin quality within weeks (src-10) — an anecdotal, uncontrolled account.
Evidence limitation as a safety consideration
Because several sources note that no human trial has tested Pal-GHK alone and no published study has measured its in vivo penetration (src-8, src-16), the human safety experience for the isolated peptide specifically (as opposed to the Matrixyl 3000 complex and low-concentration cosmetic use assessed by CIR) is limited.
Reconstitution and handling
Dosing & Preparation
No dose has been established for this compound as a therapeutic. There is no FDA/EMA label for Palmitoyl Tripeptide-1; a vendor guide explicitly states it is not FDA-approved for therapeutic use, is not approved for injection, and is available for research purposes only (src-2). The figures below are what sources report — for topical cosmetic formulation contexts — not medical guidance, and they conflict sharply depending on whether 'pure peptide' or 'complex/formulation' concentration is meant.
Reported use concentrations (topical, cosmetic)
- The CIR Expert Panel reports typical use concentrations of these ingredients are less than 10 ppm (src-1); a tier-4 site similarly states under 10 ppm (<0.001%) in finished product (src-9).
- A vendor dosing guide gives a standard topical range of 2-10 ppm, with most commercial products at 3-5 ppm (src-2).
- A peptide reference site states the peptide is effective at 0.5-3 ppm pure peptide in a finished formulation, with a typical topical range of 2-5% applied twice daily (src-6).
- A peptide vendor claims usage at 100-500 ppm, with a wrinkle-reduction protocol of 3-5% complex twice daily and a skin-barrier protocol of 1-2% complex once daily (src-10).
These ranges are inconsistent and largely reflect the difference between pure-peptide and complex/formulation concentrations; treat them as reported figures, not consensus.
Application timing (reported)
- A vendor source states twice-daily application showed superior efficacy versus single daily dosing in 12-week comparative studies measuring dermal thickness by ultrasound (src-2).
- A vendor guide describes a typical application cycle of 12-24 weeks of continuous use to assess dermal remodeling based on collagen-synthesis timelines (src-2); other sources report visible results after 4-8 weeks (src-6, src-10) or 8-12 weeks (src-7).
- A clinical trial reports nighttime application boosting nighttime collagen synthesis and working synergistically with daytime baicalin via circadian-coordinated application (src-17, src-65).
Physicochemical / delivery notes
A vendor source notes the 342.5 Da base-peptide molecular weight falls within the optimal range for topical delivery (under 500 Da) (src-2, src-13). Note that 342.5 Da is the weight of the unconjugated GHK peptide; the actual palmitoylated molecule delivered — palmitoyl tripeptide-1 — is reported by most sources at ~578 Da (formula C30H54N6O5), which exceeds the cited 500 Da threshold, so the '<500 Da' penetration rationale does not straightforwardly apply to the lipopeptide itself. Reported transdermal figures come from in vitro Franz diffusion-cell models and vendor formulation data, not human PK: 12-15% transdermal penetration within 24 hours versus 2-3% for unconjugated GHK (src-12); a liposomal suspension achieving 18-22% bioavailability, a hydrogel matrix 8-12%, and a research solution range of 0.5-20 ppm (src-16 for src-2). A tier-2 review notes unmodified GHK is hydrophilic with poor topical bioavailability (high aqueous solubility, low partition coefficient) and that chemical modification with a hydrophobic moiety increases its permeability (src-16, src-7, src-64).
Storage (vendor)
A peptide vendor recommends storage at -20°C or below (-80°C for long-term storage up to 2-3 years; 2-8°C for short-term), and states 4 weeks (28 days) of optimal potency when reconstituted with bacteriostatic water (src-10). Reconstitution volume determines final concentration and is a calculation about the container: dividing the vial's peptide mass by the volume of bacteriostatic water added yields the per-mL concentration.
No human trial has established or validated any injection dose; the compound as described in these sources is a topical cosmetic ingredient.
Sources
Ordered by evidence quality — the strongest first.
- Palmitoyl Tripeptide-1: Collagen Peptide Skin Guide(opens in a new tab)Tier 1Web · peptahub.com · 2026
- Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism.(opens in a new tab)Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2026
- A framework for the safety evaluation of peptides in cosmetics(opens in a new tab)Tier 2Web · pmc.ncbi.nlm.nih.gov
- Bioactive peptides in cosmetic formulations: Review of current in vitro and ex vivo evidence(opens in a new tab)Tier 2Web · sciencedirect.com
- Palmitoyl copper peptide and acetyl tyrosine complex enhances melanin production in both A375 and B16 cell lines.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
- Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
- Development of a LC-MS/MS method to monitor palmitoyl peptides content in anti-wrinkle cosmetics.(opens in a new tab)Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2009
- Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review(opens in a new tab)Tier 3Web · pmc.ncbi.nlm.nih.gov
- Palmitoyl Tripeptide-1 (Pal-GHK, Biopeptide CL, Palmitoyl Oligopeptide) | Peptide List(opens in a new tab)Tier 3Web · peptidelist.org
- Safety Assessment of Tripeptide-1, Hexapeptide-12, their Metal Salts ...(opens in a new tab)Tier 3Web · cir-safety.org
- Palmitoyl Tripeptide-1: Evidence & Research | Peptidings(opens in a new tab)Tier 3Web · peptidings.com · 2026
- PAL-GHK (Palmitoyl Tripeptide-1): Collagen-Boosting Peptide Research | PeptideGuide(opens in a new tab)Tier 3Web · peptideguide.com · 2026
- Palmitoyl Tripeptide-1 (Pal-GHK): Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)Tier 3Web · peptideinsight.com · 2026
- Pal-GHK (Palmitoyl Tripeptide-1) Dosage Guide: How Much(opens in a new tab)Tier 3Web · mypeptidematch.com · 2026
- Palmitoyl Tripeptide-1 Dosing, Need to Know… | Peptide Initiative(opens in a new tab)Tier 4Web · peptideinitiative.com